



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

8 March 2018
EMA/848685/2017

Public summary of opinion on orphan designation

Metformin and L-citrulline for the treatment of Duchenne muscular dystrophy

On 17 January 2018, orphan designation (EU/3/17/1965) was granted by the European Commission to Duchenne UK, United Kingdom, for metformin and L-citrulline for the treatment of Duchenne muscular dystrophy.

What is Duchenne muscular dystrophy?

Duchenne muscular dystrophy (DMD) is a genetic disease that gradually causes weakness and atrophy (wasting) of muscles. It mainly affects boys, and usually starts before the age of six years. The muscle weakness usually starts in the hips and legs, before affecting the arms, chest and the heart. Patients with DMD lack normal dystrophin, a protein found in muscles. Because this protein helps to protect muscles from injury as muscles contract and relax, in patients with DMD the muscles become weaker and eventually stop working.

DMD causes long-term disability and is life threatening because of its effects on the heart and the respiratory muscles (muscles that are used to breathe). The disease usually leads to death in early adulthood.

What is the estimated number of patients affected by the condition?

At the time of designation, DMD affected approximately 0.5 in 10,000 people in the European Union (EU). This was equivalent to a total of around 26,000 people^{*}, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

What treatments are available?

At the time of designation, the medicine Translarna (ataluren) was authorised in the EU for the treatment of a small group of patients with DMD caused by a particular type of mutation (change), called a nonsense mutation, in the dystrophin gene. Patients also received supportive treatment such as physiotherapy.

^{*}Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 515,700,000 (Eurostat 2017).



The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with DMD because early data indicate that it could slow down the decline in muscle function in a wider patient population than with the authorised treatment. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

This medicine contains metformin and L-citrulline. In DMD, metformin is thought to protect muscle function by increasing the action of AMP-activated protein kinase (AMPK), an enzyme that regulates the energy balance of cells, including muscle cells. L-citrulline has been shown to reduce muscle wasting. The combined actions of metformin and L-citrulline are expected to help improve muscle function and slow down the progression of the disease.

What is the stage of development of this medicine?

The effects of the medicine have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with the medicine in patients with DMD were ongoing.

At the time of submission, the medicine was not authorised anywhere in the EU for DMD or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 7 December 2017 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

For more information

Sponsor's contact details:

Contact details of the current sponsor for this orphan designation can be found on EMA website, on the medicine's [rare disease designations page](#).

For contact details of patients' organisations whose activities are targeted at rare diseases see:

- [Orphanet](#), a database containing information on rare diseases, which includes a directory of patients' organisations registered in Europe;
- [European Organisation for Rare Diseases \(EURORDIS\)](#), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

Translations of the active ingredient and indication in all official EU languages¹, Norwegian and Icelandic

Language	Active ingredient	Indication
English	Metformin and L-citrulline	Treatment of Duchenne muscular dystrophy
Bulgarian	Метформин и L-цитрулин	Лечение на мускулна дистрофия на Duchenne
Croatian	Metformin i L-citrulin	Liječenje Duchenneove mišićne distrofije
Czech	Metformin a L-citrulin	Léčba pacientů s Duchennovou muskulární dystrofií
Danish	Metformin og L-citrullin	Behandling af Duchenne muskeldystrofi
Dutch	Metformine en L-citrulline	Behandeling van Duchenne spierdystrofie
Estonian	Metformiin ja L-tsitrulliin	Duchenne'i lihasdüstroofia ravi
Finnish	Metformiini ja L-sitrulliini	Duchennen lihasdystrofian hoito
French	Metformine et L-citrulline	Traitement de la dystrophie musculaire de Duchenne
German	Metformin und L-Citrullin	Behandlung der Duchenne-Muskeldystrophie
Greek	Μετφορμίνη και L-κίτρουλλίνη	Θεραπεία της μυϊκής δυστροφίας Duchenne
Hungarian	Metformin és L-citrullin	Duchenne dystrophia kezelése
Italian	Metformina e L-citrullina	Trattamento della distrofia muscolare di tipo Duchenne
Latvian	Metformīns un L-citrulīns	Dišēna muskuļu distrofijas ārstēšana
Lithuanian	Metforminas su L-citrulinu	Duchenne (Diušeno) raumenų distrofijos gydymas
Maltese	Metformina u L-citrulline	Kura tad-distrofija muskolari tat-tip Duchenne
Polish	Metformina i L-cytrulina	Leczenie zaniku mięśni typu Duchenne'a
Portuguese	Metformina e L-citrulina	Tratamento da distrofia muscular de Duchenne
Romanian	Metformină și L-citrulină	Tratamentul distrofiei musculare Duchenne
Slovak	Metformín a L-citrulín	Liečba Duchenneovej muskulárnej dystrofie
Slovenian	Metformin in L-citrulin	Zdravljenje Duchenneove mišične distrofije
Spanish	Metformina y L-citrulina	Tratamiento de la distrofia muscular de Duchenne
Swedish	Metformin och L-citrullin	Behandling av Duchennes muskeldystrofi
Norwegian	Metformin og L-citrullin	Behandling av Duchennes muskeldystrofi
Icelandic	Metfoíín og L-sítrúllín	Meðferð á Duchenne vöðvarýrnun

¹ At the time of designation